Heron Therapeutics, INC. /De/ (HRTX) — 10-Q Filings

All 10-Q filings from Heron Therapeutics, INC. /De/. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Heron's Q3 Sales Up 16%, But Debt Extinguishment Drives Net Loss Spike — Nov 4, 2025 Risk: high
Heron Therapeutics, Inc. reported net product sales of $38.213 million for the three months ended September 30, 2025, an increase of 16.4% from $32.810 million
Heron Therapeutics Narrows Q2 Loss, Boosts Revenue by 11.7% — Aug 8, 2025 Risk: medium
HERON THERAPEUTICS, INC. reported a net loss of $29.7 million for the three months ended June 30, 2025, a significant improvement from the net loss of $49.5 mil
Heron Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: medium
Heron Therapeutics, Inc. (HRTX) filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance, including sales revenue
Heron Therapeutics Files Q3 2024 10-Q Report — Nov 12, 2024 Risk: medium
Heron Therapeutics, Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial statements and disclosures are det
Heron Therapeutics Files Q2 2024 10-Q — Aug 6, 2024 Risk: medium
Heron Therapeutics, Inc. filed its Q2 2024 10-Q report on August 6, 2024, detailing its financial performance for the quarter ending June 30, 2024. The company'
Heron Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: medium
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Heron Therapeutics, Inc. filed a 10-Q report for the period en

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX